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Abstract
Introduction: There have been incompatible evidences about the prognostic value of 
HbA1c on the adverse outcomes in acute coronary syndrome. Also, these data are so 
limited in nondiabetic patients with unstable angina.
Methods: In this cross-sectional study, HbA1c level of 231 nondiabetic patients admitted 
with unstable angina, was measured using high performance liquid affinity chromatography 
(HPLC) at admission. Then transthoracic echocardiography (TTE) was performed for 
evaluation of ejection fraction (EF) using Simpson method.
Results: Our data revealed that HbA1c was significantly higher in patients with EF≤ 50% 
in comparison with EF>50% group (P value=0.01).
Conclusions: HbA1c may be a helpful prognostic marker in nondiabetic patients admitted 
in emergency department with diagnosis of unstable angina.
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INTRODUCTION
Higher level of Glycated hemoglobin A1c (HbA1c) as a 
marker of chronic glucose dysregulation and accelerated 
atherosclerosis has been shown to be a prognostic factor in 
cardiovascular disease and congestive heart failure. More-
over, HbA1c has been suggested as a marker of adverse 
outcomes in the setting of acute coronary syndromes [1-
5]. Stress induced hyperglycemia even in non-diabetics, 
is related with enhanced activation of stress responsive 
kinases and initiation of apoptosis and cardiac cell necro-
sis, which sequentially results in systolic and diastolic dys-
function [6, 7].
Although an association between HbA1c level and adverse 
outcomes has been explained in diabetic patients with acute 
coronary syndromes, there are limited data in nondiabetic 
patients with unstable angina [8].
Therefore, the primary objective of this study was to de-
termine the association of HbA1c levels at admission and 
ejection fraction (EF) in nondiabetic patients with unstable 
angina.
METHODS
This was a cross-sectional study conducted from April 2013 
to March 2014 on patients admitted in coronary chest pain 
unit of Modarres hospital. Those nondiabetic patients di-
agnosed with unstable angina were selected. The exclusion 
criteria were documented diabetes mellitus, ST elevation 
MI (STEMI), None-ST elevation MI (NSTEMI), HbA1c 
≥ 6.5% or Lab test indicative of diabetes mellitus, history of 
definite MI, history of congestive heart failure and history 
of chronic kidney disease.
For each patient with diagnosis of unstable angina [9], 
HbA1c level was determined using high performance liquid 
affinity chromatography (HPLC) at admission. Then trans-
thoracic echocardiography (TTE) was performed to eval-
uate EF using the Simpson method. Finally, patients were 
divided into two groups including EF > 50% and EF ≤ 50%. 
The Institutional Review Board approved the study proto-
col and patients provided informed written consent. Statis-
tical analyses were performed by SPSS statistical software 
(version 16). Independent sample T-test was used for quan-
titative studies. P value < 0.05 was considered statistically 
significant.
RESULTS
In total, 231 patients including 122 males and 109 females, 
with diagnosis of unstable angina entered the study. Mean 
age of patients was 57.1 ± 4.5 years. 130 patients had EF ≤ 
50% and 101 patients EF > 50%. The mean level of HbA1c 
was 5.1% ± 0.43% for all patients. Mean level of HbA1c was 
5.9% ± 0.51% for EF ≤ 50% group and 4.2% ± 0.37% for EF 
> 50% group. Data analysis revealed that HbA1c was sig-
nificantly higher in patients with EF ≤ 50% in comparison 
with EF > 50% group (P value = 0.01). Table 1 shows de-
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Table 1. Demographic and Biochemical Data of the Two Groups of Non-diabetic Patients With Unstable Angina Including EF ≤ 50% 
Group and EF > 50% Group. HbA1c Was Significantly Higher in Patients With EF ≤ 50% in Comparison With EF > 50% Group
EF ≤ 50% group, N = 122 EF > 50% group, N = 109
Age 59.2 ± 3.3 55 ± 5.8
Gender
Male 63 (51.6%) 59 (54.1%)
Female 59 (48.4%) 50 (45.9%)
HbA1c level, % 5.9 ± 0.51 4.2 ± 0.37
Data in table are presented as Mean ± SD or No. (%)
DISCUSSION
The key finding of the current study was that HbA1c level at 
admission is considerably related with reduced ejection frac-
tion in diagnosed nondiabetic patients with unstable angina. 
Previous studies showed that enhanced HbA1c is related 
with higher cardiovascular risk in patients with and without 
diabetes [8, 10].
Another study on 50 patients with acute coronary syndrome 
including unstable angina, NSTEMI and STEMI determined 
that HbA1c at admission is a strong predictor of LV systolic 
dysfunction as a main adverse event of acute coronary syn-
drome in patients not known to be diabetics [11].
Measurement of glycated forms of hemoglobin presents a 
trustworthy reflection of the level of general glucometabol-
ic status in the prior 8–12 weeks. It can be considered as an 
indicator for diabetic control. There have been inconsistent 
evidences about the prognostic value of HbA1c on adverse 
outcomes in acute coronary syndrome [3-5].
In a study performed in Asian Indians with normal glucose 
tolerance, a strong correlation of HbA1c and cardiovascular 
risk factors was established. Normal glucose tolerance pa-
tients with three or more metabolic abnormalities had the 
highest HbA1c levels and an HbA1c cut off point of ≥ 6.5% 
was found to be effective in predicting both metabolic syn-
drome and coronary artery disease [12, 13].
Our study focused only on patients with unstable angina and 
those with STEMI and NSTEMI were excluded. The study 
results emphasized on relation between HbA1c level as a 
marker of accelerated atherosclerosis and reduced EF on TTE 
in nondiabetic unstable angina patients. Moreover, another 
investigation showed HbA1c level as a predictor of fatal and 
nonfatal cardiovascular events in nondiabetic peritoneal dial-
ysis patients [14].
On the other hand, one study suggested that HbA1c levels 
before admission are not related with short-term cardiovas-
cular outcome in diabetic patients admitted with acute cor-
onary syndrome [15]. This study can serve as a trigger for 
future investigations evaluating association of HbA1c and ad-
verse outcomes in nondiabetic patients with unstable angina 
and developing new prognostic algorithm and cut off points 
for HbA1c in diabetic and nondiabetic patients with unstable 
angina.
Our study showed that HbA1c in unstable angina was con-
siderably higher in nondiabetic patients with EF ≤ 50% in 
comparison with EF > 50% group. This finding emphasizes 
this point that HbA1c may be a helpful prognostic marker 
in nondiabetic patients admitted in emergency departments 
with unstable angina. Nevertheless, detailed data about the 
prognostic role of HbA1c is to somehow controversial, and 
this study with such a relatively small size cannot clarify all 
the remaining doubts.
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